Diabetic Retinopathy: Market View

This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics.

• In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData's epidemiology forecast.
• Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR.
• The DR pipeline holds 140 molecules, with three assets in the pre-registration stage, eight assets in Phase III development, and another 15 in Phase II.
• Over the past decade, 376 clinical trials have been conducted in DR. The year with the most studies initiated was 2017, with 44 trials, followed by 2024 with 41 trials.
• Over the past decade, licensing agreements in North America represented a major share (25.6%) of transactions.
• The consensus from PMR was that anti-VEGF therapies are effective and marketed by renowned, well-established pharmaceutical companies. Notwithstanding the advantages of anti-VEGF drugs, there is a significant unmet need for innovative therapies that target different pathophysiological components of DR.

Scope

GlobalData's Diabetic Retinopathy: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Diabetic Retinopathy Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Diabetic Retinopathy Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.